MicroRNA-190 regulates hypoxic pulmonary vasoconstriction by targeting a voltage-gated K⁺ channel in arterial smooth muscle cells.
Pulmonary arterial hypertension (PAH) is associated with sustained vasoconstriction, profound structural remodeling of vasculatures and alterations in Ca(2+) homeostasis in arterial smooth muscle cells (SMCs), while the underlying mechanisms are still elusive. By regulating the expression of proteins, microRNAs (miRNAs) are known to play an important role in cell fates including differentiation, apoptosis and proliferation, and may be involved in the development of PAH. Based on our previous study, hypoxia produced a significant increase of the miR-190 level in the pulmonary artery (PA), here, we used synthetic miR-190 to mimic the increase in hypoxic conditions and showed evidence for the effects of miR-190 on pulmonary arterial vasoconstriction and Ca(2+) influx in arterial SMCs. Synthetic miR-190 remarkably enhanced the vasoconstriction responses to phenylephrine (PE) and KCl. The voltage-gated K(+) channel subfamily member, Kcnq5, mRNA was shown to be a target for miR-190. Meanwhile, miR-190 antisense oligos can partially reverse the effects of miR-190 on PASMCs and PAs. Therefore, these results suggest that miR-190 appears to be a positive regulator of Ca(2+) influx, and plays an important role in hypoxic pulmonary vascular constriction.
Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University, China; Department of Biopharmaceutical Key Laboratory of Heilongjiang Province, 157 Baojian Road, Nangang District, Harbin, Heilongjiang, 150081, PR China.
Shan-Shan
SS
Li
Ya-Juan
YJ
Ran
Dan-Dan
DD
Zhang
Shu-Zhen
SZ
Li
Daling
D
Zhu
D020413:3' Untranslated Regions / Q000235:genetics; D000818:Animals; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000502:physiology; D015870:Gene Expression; D057809:HEK293 Cells; D006801:Humans; D000860:Hypoxia; D066298:In Vitro Techniques; D051656:KCNQ Potassium Channels / Q000235:genetics* / Q000378:metabolism; D035683:MicroRNAs / Q000235:genetics*; D009130:Muscle, Smooth / Q000166:cytology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism*; D010656:Phenylephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011651:Pulmonary Artery / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D051381:Rats; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014661:Vasoconstriction / Q000187:drug effects / Q000235:genetics* / Q000502:physiology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D020413:3' Untranslated Regions; D051656:KCNQ Potassium Channels; C501028:Kcnq5 protein, rat; C551254:MIRN190 microRNA, rat; D035683:MicroRNAs; D014662:Vasoconstrictor Agents; D010656:Phenylephrine; D011189:Potassium Chloride; D002118:Calcium
Ca2+ INFLUX; HYPOXIC PULMONARY VASCULAR CONSTRICTION; Kcnq5; Kv7.5; microRNA